

Drug Monograph

Drug/Drug **Antara™ (fenofibrate) capsule / peroxisome proliferator**
 Class: **receptor alpha (PPAR α) activator**
 Prepared for: MO HealthNet
 Prepared by: Xerox Heritage, LLC

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.	
Dosage Forms:	Each capsule of Antara™ 30 mg contains 30 mg of fenofibrate. Each 90 mg capsule of Antara™ contains 90 mg of fenofibrate.	
Manufacturer:	Manufactured for: Lupin Pharma, Baltimore, Maryland 21202 United States. Manufactured by: Lupin Limited, Goa - 403 722 INDIA.	
Indications:	Antara™ is a peroxisome proliferator receptor alpha (PPAR α) activator indicated as an adjunct to diet to reduce elevated LDL-C, Total-C, triglycerides, and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia and to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia.	
Costs:	\$2.18 per capsule of 30 mg Antara™ and \$6.41 per capsule of 90 mg Antara™ WholesaleAcquisitionCost	
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List and is a non-preferred agent.	
Status Recommendation:	<input type="checkbox"/> Prior Authorization (PA) Required <input type="checkbox"/> Fiscal Edit	<input type="checkbox"/> Open Access <input checked="" type="checkbox"/> PDL
Type of PA Criteria:	<input type="checkbox"/> Increased Risk of ADE <input type="checkbox"/> Appropriate Indications	<input checked="" type="checkbox"/> Non-Preferred Agent <input type="checkbox"/> No PA Required

Prepared By: Katie Wilbers, PharmD
 Date: February 12, 2014